The FDA cleared Celcuity’s Revtorpyk (gedatolisib) on July 14 for HR+/HER2- breast cancer patients without a PIK3CA mutation who’ve progressed on at least one line of endocrine therapy, paired with fulvestrant and, optionally, Pfizer’s Ibrance. I checked the approval notice: dosing is 180 mg IV, weekly, on days 1, 8, and 15 of every 28-day cycle, until progression or unacceptable toxicity.
The stock did what you’d expect. Shares closed at $111.05, up from $103.79 the session before, a roughly 7% pop on approval day. Celcuity’s press release sets commercial launch for late Q3 2026 and a Q3 supplemental filing for the PIK3CA-mutant cohort, built on the same VIKTORIA-1 trial that carried the wild-type indication through.
Here’s the part worth sitting with: Celcuity has exactly one drug, with no backup candidate and no second pathway program behind gedatolisib on the pipeline slide. Leerink’s Andrew Berens told Fierce that any company tracking toward multi-blockbuster revenue by decade’s end is a strategic target by default. A single-asset company chasing a $10 billion valuation is a cleaner acquisition thesis than a five-program platform. That logic cuts both ways: no cushion if gedatolisib stumbles in prostate cancer, where it’s still in phase 1/2.
The complication is delivery. Revtorpyk is IV, weekly, indefinitely, and Berens pegs first-line patients at four years on therapy. That’s a lot of infusion-chair time against oral competitors in a disease that already has options. Celcuity says an injectable version is coming. Worth watching whether it lands before a suitor decides the logistics are someone else’s problem.
Rebecca Lauren